Literature DB >> 20496141

Asymptomatic somatostatinoma of the pancreatic head: Report of a case.

Hideo Arima1, Shoji Natsugoe, Kousei Maemura, Youichi Hata, Toru Kumanohoso, Hiroshi Imamura, Yuko Mataki, Hiroshi Kurahara, Hiroyuki Shinchi, Sonshin Takao, Takashi Aikou.   

Abstract

A 44-year-old man was attending routine follow-up 5 years after colon cancer resection, when ultrasonography detected a pancreatic tumor with a low echoic area. He had no symptoms. Computed tomography (CT) showed a protruding-type tumor, 4 cm in diameter, in the pancreatic head with central necrosis. Angiography revealed that the tumor was hypervascular. The serum somatostatin level was elevated, at 27 pg/ml (normal range, 1.0-12 pg/ml). As somatostatinoma of the pancreas was suspected, we performed pylorus-preserving pancreaticoduodenectomy. Histological and immunohistochemical staining confirmed somatostatinoma of the pancreas without nodal metastasis. Thus, if an endocrine tumor of the pancreas is suspected in a patient with a hypervascular tumor, the possibility of somatostatinoma should be included in the differential diagnosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20496141     DOI: 10.1007/s00595-008-4089-8

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  28 in total

Review 1.  Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging.

Authors:  J C Reubi
Journal:  J Nucl Med       Date:  1995-10       Impact factor: 10.057

2.  Neuroendocrine pancreatic tumors. Clinical findings in a prospective study of 84 patients.

Authors:  B Eriksson; K Oberg; B Skogseid
Journal:  Acta Oncol       Date:  1989       Impact factor: 4.089

Review 3.  Gastrointestinal neuroendocrine tumors.

Authors:  R Delcore; S R Friesen
Journal:  J Am Coll Surg       Date:  1994-02       Impact factor: 6.113

4.  Nonfunctioning islet cell tumors.

Authors:  R B Kent; J A van Heerden; L H Weiland
Journal:  Ann Surg       Date:  1981-02       Impact factor: 12.969

5.  An update of the medical treatment of malignant endocrine pancreatic tumors.

Authors:  B Eriksson; K Oberg
Journal:  Acta Oncol       Date:  1993       Impact factor: 4.089

6.  Pancreatic somatostatinoma: abundance of somatostatin-28(1-12)-like immunoreactivity in tumor and plasma.

Authors:  Y C Patel; O P Ganda; R Benoit
Journal:  J Clin Endocrinol Metab       Date:  1983-11       Impact factor: 5.958

7.  Somatostatinoma: atypical presentation of a rare pancreatic tumor.

Authors:  C Anene; J S Thompson; J Saigh; S Badakhsh; R E Ecklund
Journal:  Am J Gastroenterol       Date:  1995-05       Impact factor: 10.864

8.  Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.

Authors:  C G Moertel; M Lefkopoulo; S Lipsitz; R G Hahn; D Klaassen
Journal:  N Engl J Med       Date:  1992-02-20       Impact factor: 91.245

9.  Pancreatic somatostatinoma. Clinical features and physiological implications.

Authors:  L I Larsson; M A Hirsch; J J Holst; S Ingemansson; C Kühl; S L Jensen; G Lundqvist; J F Rehfeld; T W Schwartz
Journal:  Lancet       Date:  1977-03-26       Impact factor: 79.321

Review 10.  Pancreatic somatostatinoma: a case report and review of the literature.

Authors:  K Konomi; K Chijiiwa; T Katsuta; K Yamaguchi
Journal:  J Surg Oncol       Date:  1990-04       Impact factor: 3.454

View more
  2 in total

1.  Clinicopathological Data and Treatment Modalities for Pancreatic Somatostatinomas.

Authors:  Aikaterini Mastoraki; Dimitrios Schizas; Eleni Papoutsi; Vasiliki Ntella; Prodromos Kanavidis; Athanasios Sioulas; Marina Tsoli; Georgios Charalampopoulos; Michail Vailas; Evangelos Felekouras
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

2.  Gastric somatostatinoma: an extremely rare cause of upper gastrointestinal bleeding.

Authors:  Varayu Prachayakul; Pitulak Aswakul; Morakod Deesomsak; Ananya Pongpaibul
Journal:  Clin Endosc       Date:  2013-09-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.